Welcome to our dedicated page for Enliven Therapeutics news (Ticker: ELVN), a resource for investors and traders seeking the latest updates and insights on Enliven Therapeutics stock.
Enliven Therapeutics reports clinical-stage biopharmaceutical developments for a small-molecule oncology pipeline led by ELVN-001, a kinase inhibitor designed to target the BCR::ABL gene fusion in chronic myeloid leukemia. News commonly covers ENABLE clinical-trial updates, CML data presentations, regulatory-development topics, quarterly financial results, and preparation for later-stage development.
Company updates also include leadership and board changes, Nasdaq inducement grants, investor-conference participation, and descriptions of Enliven's precision oncology discovery process built around clinically validated biological targets and differentiated chemistry.
Enliven Therapeutics (Nasdaq: ELVN) reported second quarter 2026 results and a business update highlighted by positive Phase 1 data for ELVN-001 in chronic myeloid leukemia (CML) and progress toward Phase 3. In the 80 mg once-daily Phase 1b cohort, ELVN-001 achieved a 61% overall major molecular response (MMR) and 48% MMR by 24 weeks, with higher response rates in earlier-line patients and a favorable safety and tolerability profile across 161 treated patients.
According to Enliven, the FDA has aligned on key ENABLE-2 Phase 3 trial design components, 80 mg once-daily was selected as the Phase 3 dose, and ELVN-001 received Fast Track Designation. The company held $895.2 million in cash, cash equivalents and marketable securities as of June 30, 2026, which is expected to fund operations into 2030. Second quarter 2026 R&D expenses were $29.0 million and G&A expenses were $8.2 million, resulting in a net loss of $32.5 million.
Enliven Therapeutics (Nasdaq: ELVN) closed an upsized underwritten public offering of common stock and pre-funded warrants, including full exercise of the underwriters' option.
The company sold 10,533,334 common shares at $37.50 and pre-funded warrants for 1,733,333 shares at $37.499, raising about $460 million in gross proceeds.
Enliven Therapeutics (Nasdaq: ELVN) priced an upsized underwritten public offering of 8,933,334 common shares at $37.50 and pre-funded warrants for up to 1,733,333 shares at $37.499. Gross proceeds are expected to be about $400 million before fees, with closing targeted around June 15, 2026.
Underwriters have a 30-day option to buy up to 1,600,000 additional shares at the public price, less underwriting discounts and commissions.
Enliven Therapeutics (Nasdaq: ELVN) has commenced an underwritten public offering of $250 million in common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option to purchase up to an additional $37.5 million of common shares, subject to market and other conditions.
Enliven Therapeutics (Nasdaq: ELVN) reported updated Phase 1 ENABLE data for ELVN-001 in previously treated CML and alignment with the FDA on key Phase 3 ENABLE-2 design elements.
Among evaluable Phase 1b patients, overall MMR was 54% (61% at 80 mg QD), with 22–30% achieving DMR by 24 weeks. ELVN-001 showed a generally tolerable safety profile in 161 patients, and 80 mg QD was selected as the recommended Phase 3 dose.
Enliven Therapeutics (Nasdaq: ELVN) will host a webcast conference call on June 11, 2026 at 8:30 a.m. ET to discuss updated Phase 1 ENABLE clinical trial data for ELVN-001 in previously treated chronic myeloid leukemia, following an oral presentation at the EHA 2026 Congress.
Enliven Therapeutics (Nasdaq: ELVN) announced participation in two upcoming investor conferences. Management will join fireside chats at the TD Cowen Annual Oncology Innovation Summit on May 27 at 2:30 p.m. ET and the Jefferies Global Healthcare Conference on June 4 at 11:40 a.m. ET.
Live webcasts and 90-day replays will be available via the company's investor relations website.
Enliven Therapeutics (Nasdaq: ELVN) reported additional Phase 1 ENABLE data for ELVN-001 in chronic myeloid leukemia, accepted for an oral presentation at the EHA 2026 Congress on June 11.
The abstract shows meaningful MMR rates in heavily pretreated patients, including prior asciminib exposure, and a favorable tolerability profile with low dose reductions and discontinuations.
Enliven Therapeutics (Nasdaq: ELVN) reported Q1 2026 results and a business update on May 7, 2026. Key points: $452.4M cash, cash equivalents and marketable securities providing runway into the first half of 2029; net loss $23.6M in Q1 2026.
The company expects mid-2026 Phase 1 data for ELVN-001, plans to initiate the Phase 3 ENABLE-2 pivotal trial in H2 2026, and continues enrollment in an 80 mg once-daily Phase 1b expansion cohort.
Enliven Therapeutics (Nasdaq: ELVN) reported positive initial Phase 1b data for ELVN-001 in relapsed/refractory or intolerant CML and plans to initiate the Phase 3 ENABLE-2 pivotal trial in the second half of 2026. As of the December 22, 2025 cutoff, 60 patients were enrolled and cohort MMR rates by 24 weeks reached 47% (80 mg) and 69% (60/120 mg).
The company held $462.6 million in cash, cash equivalents and marketable securities at December 31, 2025, expected to fund operations into the first half of 2029. Management and board changes were completed in late 2025 and early 2026.